Biotech entity
pharma is the sole category represented across all 1 tracked stories. AppLovin is most often covered alongside Federal Reserve, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention AppLovin, all published on August 4, 2026.
Last mentioned: Aug 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. AppLovin is most often covered alongside Federal Reserve, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention AppLovin, all published on August 4, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AppLovin. Shared-story counts are live from our verified record — not editorial picks.
Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors.
AppLovin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
